


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Currently amended) A compound of the Formula (I-1):



wherein:

X is alkylene optionally interrupted by one or more -O- groups;

Z is -C(O)-;

R₁₋₁ is selected from the group consisting of:

hydrogen,

alkyl,

phenyl ~~aryl~~,

~~alkylene-aryl~~,

~~heteroaryl~~,

~~alkylene heteroaryl~~,

-N(CH₃)(OCH₃), and

~~alkyl~~ ~~[[,]]~~ ~~or phenyl~~, ~~aryl~~, ~~alkylene-aryl~~, ~~heteroaryl~~, ~~or alkylene heteroaryl~~ substituted

by one or more substituents selected from the group consisting of:

halogen,

~~cyano~~,

~~nitro~~,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,
haloalkoxy, and
alkyl;
~~NH SO₂ R₁₋₄;~~
~~NH C(O) R₁₋₄;~~
~~NH C(O) NH₂;~~
~~NH C(O) NH R₁₋₄; and~~
~~N₃;~~

~~R₁₋₄ is selected from the group consisting of:~~

~~alkyl;~~
~~aryl;~~
~~alkylene aryl;~~
~~heteroaryl;~~
~~alkylene heteroaryl; and~~

~~alkyl, aryl, alkylene aryl, heteroaryl, or alkylene heteroaryl substituted by one or more substituents selected from the group consisting of:~~

~~halogen;~~
~~cyano;~~
~~nitro;~~
~~alkoxy;~~
~~dialkylamino;~~
~~alkylthio;~~
~~haloalkyl;~~
~~haloalkoxy;~~
~~alkyl; and~~
~~N₃; and~~

R₂ is selected from the group consisting of:

hydrogen,
alkyl,

hydroxyalkyl, and

alkyloxyalkyl;

~~R_{45}~~

~~$\text{X}'\text{R}_{45}$~~

~~$\text{X}'\text{Y}'\text{R}_{45}$ and~~

~~$\text{X}'\text{R}_{55}$~~

X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, and heteroarylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene, or heteroarylene, and optionally interrupted by one or more O groups;

Y' is selected from the group consisting of:

~~$\text{S}(\text{O})_{0-2}$~~ ,

~~$\text{S}(\text{O})_2\text{N}(\text{R}_8)$~~ ,

~~$\text{C}(\text{R}_6)$~~ ,

~~$\text{C}(\text{R}_6)\text{O}$~~ ,

~~$\text{O}\text{C}(\text{R}_6)$~~ ,

~~$\text{O}\text{C}(\text{O})\text{O}$~~ ,

~~$\text{N}(\text{R}_8)\text{Q}'$~~ ,

~~$\text{C}(\text{R}_6)\text{N}(\text{R}_8)$~~ ,

~~$\text{O}\text{C}(\text{R}_6)\text{N}(\text{R}_8)$~~ ,

~~$\text{C}(\text{R}_6)\text{N}(\text{OR}_9)$~~ ,

~~$\text{N-Q}'$~~


~~$\text{N-R}_7\text{N-Q}'$~~

~~V-N~~

, and

~~R₄ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, and alkynyl, oxo;~~

~~R₅ is selected from the group consisting of:~~



~~R₆ is selected from the group consisting of =O and =S;~~

~~R₇ is a C₂₋₇ alkylene;~~

~~R₈ is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;~~

~~R₉ is selected from the group consisting of hydrogen and alkyl;~~

~~R₁₀ is C₃₋₈ alkylene;~~

~~A is selected from the group consisting of O, C(O), S(O)₀₋₂, CH₂, and N(R₄);~~

~~Q' is selected from the group consisting of a bond, C(R₆), C(R₆)C(R₆), S(O)₂, and S(O)₂N(R₈);~~

~~V is selected from the group consisting of C(R₆), O C(R₆), and S(O)₂;~~

~~a and b are independently integers from 1 to 6 with the proviso that a+b is ≤ 7;~~

~~R_A and R_B are each independently selected from the group consisting of:~~

~~hydrogen,~~

~~halogen,~~

~~alkyl,~~

~~alkenyl,~~

~~alkoxy,~~

alkylthio, and

~~-N(R₉)₂;~~

~~or~~ R_A and R_B are taken together to form either a fused aryl ring that is unsubstituted or substituted by one or more R groups, or a fused 5 to 7 membered saturated ring that is unsubstituted or substituted by one or more R_a groups;

R is selected from the group consisting of:

fluoro,

alkyl,

haloalkyl,

alkoxy, and

~~-N(R₉)₂; and~~

R_a is selected from the group consisting of:

halogen,

hydroxy,

alkyl,

alkenyl,

haloalkyl,


alkoxy,

alkylthio, and

~~-N(R₉)₂;~~

or a pharmaceutically acceptable salt thereof.

2. (Currently amended) A compound of the Formula (I-2):



I-2

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

n is an integer from 0 to 4;

Z is -C(O)-;

R₁₋₁ is selected from the group consisting of:

hydrogen,

alkyl,

phenyl ~~aryl~~,

~~alkylene-aryl~~,

~~heteroaryl~~,

~~alkylene-heteroaryl~~,

-N(CH₃)(OCH₃), and

alkyl ~~[[.]]~~ or phenyl, ~~aryl~~, ~~alkylene-aryl~~, ~~heteroaryl~~, ~~or alkylene-heteroaryl~~ substituted

by one or more substituents selected from the group consisting of:

halogen,

~~cyano~~,

~~nitro~~,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy, and

alkyl;

~~-NH-SO₂-R₁₋₄~~;

~~-NH-C(O)-R₁₋₄~~;

~~-NH-C(O)-NH₂~~;

~~-NH-C(O)-NH-R₁₋₄~~ ~~and~~

~~-N₃~~;

~~R₁₋₄ is selected from the group consisting of:~~

~~alkyl~~;

~~aryl,~~
~~alkylene-aryl,~~
~~heteroaryl,~~
~~alkylene heteroaryl, and~~
~~alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene heteroaryl substituted by one or~~
~~more substituents selected from the group consisting of:~~


~~halogen,~~
~~cyano,~~
~~nitro,~~
~~alkoxy,~~
~~dialkylamino,~~
~~alkylthio,~~
~~haloalkyl,~~
~~haloalkoxy, alkyl, and~~
~~-N₃;~~

and R is selected from the group consisting of:

fluoro,
alkyl,
haloalkyl,
alkoxy, and
-N(R₉)₂;








R₂ is selected from the group consisting of:

hydrogen,
alkyl,
hydroxyalkyl, and
alkyloxyalkyl;
~~-R₄₅~~
~~-X'-R₄₅~~
~~-X'-Y'-R₄₅, and~~



~~X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, and heteroarylene, wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated with arylene or heteroarylene, and optionally interrupted by one or more~~
~~O~~ ~~groups;~~


~~Y' is selected from the group consisting of:~~

~~, and~~

R_4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl, wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, and alkylheteroarylenyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy,

hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl, amino, alkylamino, dialkylamino, (dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl, and alkynyl, oxo;

R_5 is selected from the group consisting of:



R_6 is selected from the group consisting of $=O$ and $=S$;

R_7 is a C_{2-7} alkylene;

R_8 is selected from the group consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl;

R_9 is selected from the group consisting of hydrogen and alkyl;

R_{10} is C_{3-8} alkylene;

A is selected from the group consisting of O , $C(O)$, $S(O)_{0-2}$, CH_2 , and $N(R_4)$;

Q' is selected from the group consisting of a bond, $C(R_6)$, $C(R_6)C(R_6)$, $S(O)_2$, and $S(O)_2N(R_8)$;


V is selected from the group consisting of $C(R_6)$, $O-C(R_6)$, and $(O)_2$;

and a and b are independently integers from 1 to 6 with the proviso that $a+b$ is ≤ 7 ;

or a pharmaceutically acceptable salt thereof

3.4. (Canceled)

5. (Currently amended) A compound of the Formula (Ia):



Ia

wherein:

X is alkylene optionally interrupted by one or more -O- groups;

n is an integer from 0 to 4;

R₁₋₁ is selected from the group consisting of:

hydrogen,

alkyl,

phenyl ~~aryl~~,

~~alkylene-aryl~~,

~~heteroaryl~~,

~~alkylene-heteroaryl~~,

-N(CH₃)(OCH₃), and

alkyl ~~[[,]]~~ or phenyl, ~~aryl~~, ~~alkylene-aryl~~, ~~heteroaryl~~, ~~or alkylene-heteroaryl~~ substituted

by one or more substituents selected from the group consisting of:

halogen,

~~cyano~~,

~~nitro~~,

alkoxy,

dialkylamino,

alkylthio,

haloalkyl,

haloalkoxy, and

alkyl,

~~-NH-SO₂-R₁₋₄~~,

~~-NH-C(O)-R₁₋₄~~,

~~-NH-C(O)-NH₂~~,

~~-NH-C(O)-NH-R₁₋₄~~, and

~~-N₃~~;

~~R₁₋₄ is selected from the group consisting of:~~

~~alkyl,~~

~~aryl,~~

~~alkylene-aryl,
heteroaryl,
alkylene heteroaryl, and
alkyl, aryl, alkylene-aryl, heteroaryl, or alkylene heteroaryl substituted by one or
more substituents selected from the group consisting of:~~

~~halogen,
cyano,
nitro,
alkoxy,
dialkylamino,
alkylthio,
haloalkyl,
haloalkoxy,
alkyl, and
-N₃;~~

R is selected from the group consisting of:

fluoro,
alkyl,
haloalkyl,
alkoxy, and
-N(R₉)₂;

R₂ is selected from the group consisting of:

hydrogen,
alkyl,
hydroxyalkyl, and
alkyloxyalkyl;
hydrogen,
alkyl,
alkenyl,

~~aryl,~~
~~heteroaryl,~~
~~heterocyclyl,~~
~~alkylene-Y-alkyl,~~
~~alkylene-Y-alkenyl,~~
~~alkylene-Y-aryl, and~~
~~alkyl or alkenyl substituted by one or more substituents selected from the group~~
~~consisting of:~~

~~hydroxy,~~
~~halogen,~~
 ~~$\text{N}(\text{R}_3)_{2,5}$,~~
 ~~$\text{C}(\text{O})\text{-C}_{1-10}\text{alkyl}$,~~
 ~~$\text{C}(\text{O})\text{-O-C}_{1-10}\text{alkyl}$,~~
 ~~$\text{N}(\text{R}_3)\text{-C}(\text{O})\text{-C}_{1-10}\text{alkyl}$,~~
 ~~N_3 ,~~
~~aryl,~~
~~heteroaryl,~~
~~heterocyclyl,~~
 ~~$\text{C}(\text{O})\text{-aryl}$, and~~
 ~~$\text{C}(\text{O})\text{-heteroaryl}$;~~

wherein:

~~Y is O or $\text{S}(\text{O})_{0-2}$;~~


~~R_3 is selected from the group consisting of:~~

~~hydrogen,~~
 ~~$\text{C}_{1-10}\text{alkyl}$, and~~
 ~~$\text{C}_{2-10}\text{alkenyl}$; and~~

R_9 is selected from the group consisting of hydrogen and alkyl;
 or a pharmaceutically acceptable salt thereof.

6.-7. (Canceled)

8. (Currently amended) A compound of the Formula (Ie):



wherein:

X is alkylene optionally interrupted by one or more -O- groups;

n is an integer from 0 to 4;

R is selected from the group consisting of:

fluoro,
alkyl,
alkoxy,
haloalkyl, and
-N(R₉)₂;

R₂ is selected from the group consisting of:

hydrogen,
alkyl,
hydroxyalkyl, and
alkyloxyalkyl;
~~hydrogen,~~
~~alkyl,~~
~~alkenyl,~~
~~aryl,~~
~~heteroaryl,~~
~~heterocyclyl,~~

alkylene-Y-alkyl,
 alkylene-Y-alkenyl,
 alkylene-Y-aryl, and
 alkyl or alkenyl substituted by one or more substituents selected from the group
 consisting of:

hydroxy,
 halogen,
~~N(R₃)₂~~,
~~C(O)-C₁₋₁₀alkyl~~,
~~C(O)-O-C₁₋₁₀alkyl~~,
~~N(R₃)-C(O)-C₁₋₁₀alkyl~~,
~~N₃~~,
 aryl,
 heteroaryl,
 heterocycyl,
~~C(O)-aryl~~, and
~~C(O)-heteroaryl~~;

wherein:

~~Y is O or S(O)₀₋₂~~; and

~~R₃ is selected from the group consisting of:~~

hydrogen,
 C₁₋₁₀alkyl, and
 C₂₋₁₀alkenyl; and

R₉ is selected from the group consisting of hydrogen and alkyl;
 or a pharmaceutically acceptable salt thereof.

9.10. (Canceled)

11. (Previously presented) The compound or salt of claim 2 wherein n is 0.

12.-17. (Canceled)

18. (Currently amended) The compound or salt of claim 1 wherein R_{1-1} is selected from the group consisting of ~~aryl~~ phenyl, alkyl, and $-N(CH_3)OCH_3$.

19. (Canceled)

20. (Previously presented) The compound or salt of claim 1 wherein X is a C_{1-6} alkylene or $-(CH_2)_{2-4}-O-(CH_2)_{1-3}-$.

21. (Original) The compound or salt of claim 20 wherein X is selected from the group consisting of $-(CH_2)_{1-6}-$, $-CH_2-C(CH_3)_2-$, $-(CH_2)_2-O-CH_2-$, $-(CH_2)_3-O-CH_2-$, and $-CH_2-C(CH_3)_2-CH_2-$.

22. (Currently amended) The compound or salt of claim 1 wherein R_{1-1} is selected from the group consisting of alkyl and phenyl ~~aryl~~.

23. (Currently amended) The compound or salt of claim 1 ~~22~~ wherein R_{1-1} is selected from the group consisting of methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, *sec*-butyl, isobutyl, *tert*-butyl, *n*-pentyl, cyclopentyl, *n*-hexyl, cyclohexyl, phenyl, 4-chlorophenyl and 2,4-dichlorophenyl.

24.-25. (Canceled)

26. (Currently amended) The compound or salt of claim ~~25~~ 1 wherein R_2 is selected from the group consisting of hydrogen, hydroxymethyl, methyl, ethyl, *n*-propyl, *n*-butyl, ethoxymethyl, and 2-methoxyethyl.

27.-28. (Canceled)

29. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 1 in combination with a pharmaceutically acceptable carrier.

30. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 1 to the animal.

31. (Withdrawn) A method of treating a viral disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

32. (Withdrawn) A method of treating a neoplastic disease in an animal in need thereof comprising administering a therapeutically effective amount of a compound or salt of claim 1 to the animal.

33.-35. (Canceled)

36. (Previously presented) The compound or salt of claim 2 wherein X is a C₁₋₆ alkylene or -(CH₂)₂₋₄-O-(CH₂)₁₋₃-.

37. (Previously presented) The compound or salt of claim 36 wherein X is selected from the group consisting of -(CH₂)₁₋₆-, -CH₂-C(CH₃)₂-, -(CH₂)₂-O-CH₂-, -(CH₂)₃-O-CH₂-.

38. (Currently amended) The compound or salt of claim 2 wherein R₁₋₁ is selected from the group consisting of alkyl and phenyl ~~aryl~~.

39. (Currently amended) The compound or salt of claim 2 ~~38~~ wherein R₁₋₁ is selected from the group consisting of methyl, ethyl, *n*-propyl, isopropyl, cyclopropyl, *n*-butyl, *sec*-butyl,

isobutyl, *tert*-butyl, *n*-pentyl, cyclopentyl, *n*-hexyl, cyclohexyl, phenyl, 4-chlorophenyl and 2,4-dichlorophenyl.

40. (Canceled)

41. (Currently amended) The compound or salt of claim ~~40~~ 2 wherein R₂ is selected from the group consisting of hydrogen, hydroxymethyl, methyl, ethyl, *n*-propyl, *n*-butyl, ethoxymethyl, and 2-methoxyethyl.

42. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 2 in combination with a pharmaceutically acceptable carrier.

43. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 2 to the animal.

44.-53. (Canceled)

54. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound or salt of claim 8 in combination with a pharmaceutically acceptable carrier.

55. (Withdrawn) A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt of claim 8 to the animal.